Since previous results obtained in glioblastoma (GBM) cells showed the important role of CMA and suggested HIF-1α as a potential therapeutic target [11, 19], here we also assessed whether HIF-1α abrogation could permit the switch toward responsiveness of TMZ-resistant cells. The gene discussed is HIF1A; the disease is glioblastoma.